title: Expression and localization of maspin in cervical cancer and its role in tumor progression and lymphangiogenesis.
abstract: OBJECTIVE
  Cervical cancer is the most common malignant tumor in female reproductive tract and primarily metastasizes through the lymphatic system that will affect prognosis of patients. Maspin, a member of the serine protease inhibitors (serpins) super family, has recently been indicated as a tumor suppressor in many cancers. In this study, we investigated the clinical significance of maspin expression, especially the subcellular location of maspin and its functional role in progression and lymphangiogenesis, in cervical squamous cell carcinoma.
  
  
  METHODS
  Labelled streptavidin biotin method (LSAB) was used to determine cytoplasmic and nuclear maspin expressions, respectively, in 13 cases of normal cervix, 15 cases of cervical intraepithelial neoplasia grade 3 (CIN3), 62 cases of squamous cell carcinoma (SCC) of the uterine cervix, and 13 cases of pelvic lymphatic nodes which were all positive lymphatic nodes in our selected cancer cases. LSAB is also used to detect podoplanin which is used for counting density of lymphatic microvessels (LMVD). The clinical significance of subcellular maspin expression and the relationship between maspin expression and LMVD in cervical cancer are analyzed.
  
  
  RESULTS
  Both cytoplasmic and nuclear maspin expressions in SCC were significantly weaker than those of normal cervix and CIN3. Nuclear maspin expression showed a peak in CIN3 and then dropped in SCC. Declined maspin expression was correlated with later clinical stage, increased LMVD, and lymphatic metastasis.
  
  
  CONCLUSIONS
  Our results suggest that subcellular location of maspin expression is a potential predictive factor in tumor progression and in patients' prognosis of cervical cancer, and maspin plays a suppression role in lymphangiogenesis and metastasis.
authors: Zhiqiang
authors: Z
authors: Liu
authors: Yangyang
authors: Y
authors: Shi
authors: Wei
authors: W
authors: Meng
authors: Yufang
authors: Y
authors: Liu
authors: Kaixuan
authors: K
authors: Yang
authors: Shuhua
authors: S
authors: Wu
authors: Zhilan
authors: Z
authors: Peng
mesh_terms: D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000378:metabolism; D002294:Carcinoma, Squamous Cell / Q000378:metabolism* / Q000473:pathology / Q000601:surgery; D018450:Disease Progression; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D042583:Lymphangiogenesis / Q000502:physiology*; D008207:Lymphatic Metastasis; D008562:Membrane Glycoproteins / Q000378:metabolism; D008875:Middle Aged; D060787:Neoplasm Grading; D009361:Neoplasm Invasiveness / Q000473:pathology; D011379:Prognosis; D015843:Serpins / Q000378:metabolism*; D002583:Uterine Cervical Neoplasms / Q000378:metabolism* / Q000473:pathology / Q000601:surgery; D000098853:Podoplanin
chemical_list: D014408:Biomarkers, Tumor; D008562:Membrane Glycoproteins; D015843:Serpins; C117468:PDPN protein, human; D000098853:Podoplanin; C085344:SERPIN-B5
references: Oncogene. 2003 Jun 5;22(23):3624-34
references: 12789271
references: Folia Histochem Cytobiol. 2005;43(2):109-16
references: 16044948
references: Science. 1994 Jan 28;263(5146):526-9
references: 8290962
references: J Med Chem. 2012 Jan 26;55(2):971-5
references: 22175694
references: J Egypt Natl Canc Inst. 2005 Sep;17(3):173-83
references: 16799655
references: Invest Ophthalmol Vis Sci. 2002 Jul;43(7):2127-35
references: 12091407
references: J Korean Med Sci. 2006 Apr;21(2):309-14
references: 16614520
references: Tumour Biol. 2010 Oct;31(5):471-6
references: 20517662
references: Clin Biochem. 2001 Jun;34(4):303-7
references: 11440731
references: Gynecol Oncol. 2011 Nov;123(2):314-9
references: 21903246
references: Clin Cancer Res. 2002 Sep;8(9):2924-32
references: 12231537
references: Lab Invest. 2011 Aug;91(8):1181-7
references: 21502940
references: Clin Exp Gastroenterol. 2011;4:239-53
references: 22162927
references: Nephrol Dial Transplant. 1999;14 Suppl 1:9-11
references: 10048437
references: Breast Cancer Res Treat. 1995;36(2):169-80
references: 8534865
references: Clin Genet. 2003 Oct;64(4):282-92
references: 12974730
references: Dig Dis Sci. 2002 Aug;47(8):1831-5
references: 12184537
references: J Clin Pathol. 2007 Mar;60(3):261-6
references: 16751302
references: Histopathology. 2003 Jun;42(6):541-5
references: 12786889
references: Nat Med. 2000 Feb;6(2):196-9
references: 10655109
references: J Histochem Cytochem. 1997 Dec;45(12):1697-706
references: 9389773
references: Anticancer Res. 2001 Jul-Aug;21(4A):2351-5
references: 11724292
references: Oncol Rep. 2011 Dec;26(6):1555-60
references: 21833477
references: J Urol. 1997 Jun;157(6):2323-8
references: 9146664
references: Urology. 2010 Sep;76(3):765.e8-13
references: 20605199
references: Yakugaku Zasshi. 2012;132(2):211-4
references: 22293702
references: Br J Cancer. 2003 Mar 24;88(6):863-70
references: 12644823
references: Epigenetics. 2011 Feb;6(2):224-35
references: 20948306
references: Mod Pathol. 2005 Aug;18(8):1102-6
references: 15731774
references: Appl Immunohistochem Mol Morphol. 2012 Dec;20(6):588-94
references: 22495364
references: J Exp Clin Cancer Res. 2011 Mar 25;30:31
references: 21439064
references: PLoS One. 2011;6(9):e24595
references: 21931769
references: Curr Pharm Des. 2010 Jun;16(16):1877-81
references: 20337574
references: Oncol Rep. 2011 Jan;25(1):259-65
references: 21109985
references: Anticancer Res. 2010 Jul;30(7):2739-44
references: 20683007
references: Biochem Cell Biol. 2012 Feb;90(1):22-38
references: 22047058
references: Verh Dtsch Ges Pathol. 2004;88:237-45
references: 16892558
references: Int J Cancer. 2002 Aug 1;100(4):452-5
references: 12115529
references: Folia Morphol (Warsz). 2010 Nov;69(4):204-12
references: 21120806
references: Clin Cancer Res. 2001 Jan;7(1):93-7
references: 11205924
references: Int J Mol Med. 2012 Feb;29(2):225-30
references: 22076034